secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001558370-24-002480
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte provides FY2024 guidance: core flat to +5%; FY2023 prelim core down 25% YoY
--------------------------------------------------------------------------------

- FY2023 prelim total revenue $41.1-$41.3M (vs $44.3M in 2022); core revenue $29.6-$29.8M (vs $39.6M), down ~25%.
- SPL program-related revenue was ~$11.4M in FY2023 (vs $4.6M in 2022), driven by licensing.
- FY2024 guidance: core flat to +5%; SPL ~$3M; outlook does not include CASGEVY royalties.
- Year-end 2023 cash & investments ~$210M; expects to end 2024 with ~$175M.
- Already signed three SPLs in 2024; presenting at Cowen conference March 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024002480/0001558370-24-002480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024002480/mxct-20240304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer